- Home
- EXPI vs EYPT Comparison
EXPI vs EYPT Comparison
Compare EXPI & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EXPI | EYPT |
|---|---|---|
| Founded | 2008 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2010 | 2005 |
Fundamental Metrics
Financial Performance| Metric | EXPI | EYPT |
|---|---|---|
| Price | $6.72 | $15.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $9.75 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 875.3K | 813.4K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,147,681.00 | $7,539,000.00 |
| Revenue This Year | $6.26 | N/A |
| Revenue Next Year | $5.50 | $3,115.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 220.39 | N/A |
| 52 Week Low | $5.66 | $5.46 |
| 52 Week High | $12.23 | $19.11 |
Technical Indicators
Market Signals| Indicator | EXPI | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 62.47 | 59.39 |
| Support Level | $5.68 | $14.50 |
| Resistance Level | $11.36 | $18.99 |
| Average True Range (ATR) | 0.23 | 0.64 |
| MACD | 0.14 | 0.26 |
| Stochastic Oscillator | 98.07 | 91.22 |
Price Performance
Historical ComparisonAbout EXPI eXp World Holdings Inc.
eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.